• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors.

作者信息

Kongtim P, Adekola K, Milton D R, Ramlal R, Jimenez A, Chen J, Rondon G, Ahmed S, Kebriaei P, Betul O, Hosing C M, Popat U, Khouri I, Jabbour E, Cortes J E, Kantarjian H M, Champlin R E, Ciurea S O

机构信息

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

Department of Biostatistics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Leukemia. 2017 Jul;31(7):1654-1657. doi: 10.1038/leu.2017.118. Epub 2017 Apr 12.

DOI:10.1038/leu.2017.118
PMID:28400618
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6192023/
Abstract
摘要

相似文献

1
Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors.在酪氨酸激酶抑制剂时代，除了慢性期移植和清髓性预处理外，供体类型也会影响晚期慢性髓性白血病患者的移植生存率。
Leukemia. 2017 Jul;31(7):1654-1657. doi: 10.1038/leu.2017.118. Epub 2017 Apr 12.
2
A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation.异基因造血细胞移植后复发的 CML 患者中供者淋巴细胞输注与酪氨酸激酶抑制剂的长期疗效比较。
Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):87-92. doi: 10.1016/j.clml.2013.09.010. Epub 2013 Oct 1.
3
Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia.在 HLA 同胞供体移植后，根据 BCR-ABL 转录本水平进行个体化干预可改善慢性髓系白血病患者的 HSCT 结局。
Biol Blood Marrow Transplant. 2011 May;17(5):649-56. doi: 10.1016/j.bbmt.2010.07.023. Epub 2010 Aug 5.
4
Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party.异基因造血干细胞移植治疗酪氨酸激酶抑制剂时代的慢性髓性白血病急变期：EBMT 慢性恶性肿瘤工作组的回顾性研究。
Biol Blood Marrow Transplant. 2019 Oct;25(10):2008-2016. doi: 10.1016/j.bbmt.2019.06.028. Epub 2019 Jul 1.
5
[The role of allogeneic hematopoietic stem cell transplant in therapy of chronic myeloid leukemia in the era of tyrosine kinase inhibitors].
Zhonghua Xue Ye Xue Za Zhi. 2014 Feb;35(2):92-3. doi: 10.3760/cma.j.issn.0253-2727.2014.02.002.
6
Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.对晚期血液系统恶性肿瘤患者进行非清髓性预处理的异基因造血细胞移植。
Cytotherapy. 2001;3(4):253-60. doi: 10.1080/146532401317070880.
7
Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.酪氨酸激酶抑制剂治疗时代异基因 SCT 治疗慢性髓性白血病患者的结局。
Ann Hematol. 2013 Apr;92(4):487-96. doi: 10.1007/s00277-012-1650-8. Epub 2012 Dec 19.
8
Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?异基因干细胞移植后复发的慢性髓性白血病供体淋巴细胞输注：我们能否在不发生移植物抗宿主病的情况下预测移植物抗白血病作用？
Biol Blood Marrow Transplant. 2015 Jul;21(7):1230-6. doi: 10.1016/j.bbmt.2015.03.012. Epub 2015 Mar 19.
9
[Treatment of acute leukemias and chronic myeloid leukemias].[急性白血病和慢性髓性白血病的治疗]
Soins. 2008 Mar(723):44-5.
10
[Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].[捷克共和国慢性髓性白血病患者的异基因造血干细胞移植——1988 - 2005年结果的回顾性分析]
Vnitr Lek. 2006 Dec;52(12):1172-80.

引用本文的文献

1
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia.酪氨酸激酶抑制剂治疗与慢性期慢性髓性白血病移植相关的问题。
Leukemia. 2022 May;36(5):1227-1236. doi: 10.1038/s41375-022-01522-3. Epub 2022 Mar 25.

本文引用的文献

1
Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.使用单倍体相合相关供者与 HLA 配型相合无关供者进行淋巴瘤的减低剂量预处理移植。
Blood. 2016 Feb 18;127(7):938-47. doi: 10.1182/blood-2015-09-671834. Epub 2015 Dec 15.
2
Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission.基于注册研究的无移植物抗宿主病、无复发生存的定义：ALWP-EBMT对缓解期急性髓系白血病患者的分析
Bone Marrow Transplant. 2016 Apr;51(4):610-1. doi: 10.1038/bmt.2015.305. Epub 2015 Dec 14.
3
Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated Donor.与来自人类白细胞抗原匹配的相关或无关供体的异基因造血干细胞移植相比，单倍体相合T细胞充足移植联合移植后环磷酰胺用于60岁及以上患者的治疗
Biol Blood Marrow Transplant. 2016 Jan;22(1):119-24. doi: 10.1016/j.bbmt.2015.08.029. Epub 2015 Sep 1.
4
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.单倍体相合移植联合移植后环磷酰胺与匹配无关供者移植治疗急性髓系白血病
Blood. 2015 Aug 20;126(8):1033-40. doi: 10.1182/blood-2015-04-639831. Epub 2015 Jun 30.
5
Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors.急性髓系白血病和骨髓增生异常综合征患者接受单倍体相合供者与10/10人类白细胞抗原匹配的无关及相关供者移植的结局相似。
Biol Blood Marrow Transplant. 2014 Dec;20(12):1975-81. doi: 10.1016/j.bbmt.2014.08.013. Epub 2014 Sep 28.
6
Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis.在慢性粒细胞白血病急变期，异基因造血干细胞移植联合酪氨酸激酶抑制剂治疗与单纯酪氨酸激酶抑制剂治疗的比较。
Bone Marrow Transplant. 2014 Sep;49(9):1146-54. doi: 10.1038/bmt.2014.146. Epub 2014 Jul 21.
7
Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.与其他替代供体和匹配的同胞移植物相比，未处理的单倍体同基因移植。
Biol Blood Marrow Transplant. 2014 Oct;20(10):1573-9. doi: 10.1016/j.bbmt.2014.05.029. Epub 2014 Jun 5.
8
Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis.伊马替尼时代慢性粒细胞白血病异基因移植结局的预后因素：一项国际骨髓移植登记处（CIBMTR）分析
Bone Marrow Transplant. 2012 Jun;47(6):810-6. doi: 10.1038/bmt.2011.194. Epub 2011 Oct 10.
9
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.至少持续 2 年完全分子缓解的慢性髓性白血病患者停止伊马替尼治疗：前瞻性、多中心停止伊马替尼（STIM）试验。
Lancet Oncol. 2010 Nov;11(11):1029-35. doi: 10.1016/S1470-2045(10)70233-3. Epub 2010 Oct 19.
10
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.慢性髓性白血病：欧洲白血病网络概念与管理建议的更新
J Clin Oncol. 2009 Dec 10;27(35):6041-51. doi: 10.1200/JCO.2009.25.0779. Epub 2009 Nov 2.